研究显示，停药1 年内，心血管死亡/心衰住院风险显著增加，停用RAS抑制剂/ARNI可导致心血管死亡/心衰住院风险增加38%，停用MRA可导致风险增加36%，但停用β受体阻滞剂 影响不大。 与LVEF 改善至≥50%的患者相比，LVEF改善至40%~49%的患者如停用β受体阻滞剂，心血管死亡/心衰住院风险更高。这表明，在LVEF改善至50%之前持续使用β受体阻滞剂，预后可能会更好。

Bayer's mineralocorticoid receptor antagonist (MRA) Kerendia hit the mark as a treatment for a common form of heart failure in the FINEARTS-HF study, setting up regulatory approvals, but there is ...

The analysis included 8,728 patients with heart failure with improved EF (first recorded EF <40 percent and a later EF ≥40 percent). The researchers found that the withdrawal rates at the time of the ...

Bayer has filed its mineralocorticoid receptor antagonist (MRA) finerenone as a treatment for a common form of heart failure in the EU, fulfilling a key 2025 pipeline objective. The pharma group ...

The following is a summary of "Eplerenone, diabetes, and chronic kidney disease in patients hospitalized for acute heart failure: findings from the EARLIER trial," published in the March 2025 issue of ...

"Our results show that heart failure medications continue to provide ... "This supports the current recommendation to continue with RASi/ARNi and MRA treatment, but also opens up the possibility ...

"Our results show that heart failure medications continue to provide ... "This supports the current recommendation to continue with RASi/ARNi and MRA treatment, but also opens up the possibility ...